Er Her2 Early Breast Cancer clinical trials

Explore recruiting er her2 early breast cancer clinical trials.

Recruiting er her2 early breast cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Er Her2 Early Breast Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

SPatial Heterogeneity of INtratumoral drug distribution

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

Elacestrant versus Standard Endocrine Therapy in Women and Men with Node positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence - A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)

Italy, France, Romania, Spain, Sweden, Belgium +9 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence

Hungary, Germany, Austria, Spain, Netherlands, Romania +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease

Belgium, Spain, Hungary, Poland, Czechia, Portugal +10 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing adjuvant Elacestrant with standard endocrine treatment in genomically and/or clinically high-risk ER+/HER2- early breast cancer (ADAPTela)

Germany, Spain, Austria

Therapeutic confirmatory (Phase III) EU CTIS Study details

EORTC-1745-ETF-BCG: A Phase II study of Adjuvant PALbociclib as an Alternative to CHemotherapy in Elderly patientS with high-risk ER+/HER2- early breast cancer (APPALACHES)

Spain, Germany, Portugal, Poland, Belgium, Italy +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Er Her2 Early Breast Cancer trials by city

Er Her2 Early Breast Cancer in Toronto Er Her2 Early Breast Cancer in Vancouver Er Her2 Early Breast Cancer in Montreal Er Her2 Early Breast Cancer in Calgary Er Her2 Early Breast Cancer in Edmonton Er Her2 Early Breast Cancer in Ottawa Er Her2 Early Breast Cancer in Winnipeg Er Her2 Early Breast Cancer in Quebec City Er Her2 Early Breast Cancer in Hamilton Er Her2 Early Breast Cancer in Kitchener Er Her2 Early Breast Cancer in London Er Her2 Early Breast Cancer in Halifax Er Her2 Early Breast Cancer in New York Er Her2 Early Breast Cancer in Los Angeles Er Her2 Early Breast Cancer in Chicago Er Her2 Early Breast Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease